IMDX
Insight Molecular Diagnostics
IMDX
IMDX
56 hedge funds and large institutions have $58.2M invested in Insight Molecular Diagnostics in 2019 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 15 increasing their positions, 19 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
21% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 19
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Holders
56
Holding in Top 10
1
Calls
–
Puts
$1K
Top Buyers
| 1 | +$12.8M | |
| 2 | +$2.65M | |
| 3 | +$563K | |
| 4 |
PM
Penbrook Management
New York
|
+$398K |
| 5 |
Barclays
London,
United Kingdom
|
+$360K |
Top Sellers
| 1 | -$887K | |
| 2 | -$295K | |
| 3 | -$105K | |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$90K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$85K |